A new mini review published in Acta Neurochirurgica examines the emerging landscape of targeted treatments for brain arteriovenous malformations, or bAVMs. Authored by Jessica Youngkyung Jung, Ivan Radovanovic, and Ann Bailey, the article provides a comprehensive summary of the pathophysiology behind these vascular anomalies and the preclinical and clinical evidence supporting molecularly targeted drug therapies. The review highlights a critical shift in understanding bAVMs as a distinct disease entity driven by somatic mutations, separate from familial syndromes such as hereditary hemorrhagic telangiectasia and capillary malformation-AVM syndromes.
Brain arteriovenous malformations are characterized as abnormal tangles of vessels that shunt pressurized arterial blood directly into low-pressure veins. This structural abnormality creates a fragile vascular network that is prone to rupture, posing significant risks of hemorrhage and subsequent morbidity for affected individuals. The review notes that the risks associated with current treatment options may equal or even exceed the risks posed by the natural history of the disease itself. This precarious balance underscores an urgent need for the development and implementation of molecularly targeted therapies that can address the underlying biological mechanisms without the high procedural risks of traditional interventions.
Recent years have seen a transition toward molecular profiling, which has outlined the specific role of various somatic mutations within endothelial cells. These mutations contribute to the constitutive activation of cellular proliferation and migration, key processes in the formation and maintenance of the malformation.
The authors summarize the critical role of combinatorial treatment strategies in managing bAVMs. This includes the integration of molecular profiling to guide treatment decisions, ensuring that therapies are matched to the specific genotype of the malformation.
The review also discusses the importance of molecular profiling in the broader context of bAVM management. The article serves as a resource for researchers and clinicians interested in the molecular mechanisms of bAVM formation and the potential of targeted drugs.
Published as an open access article, the review is intended to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI, although the version shared early is subject to further edits and will be replaced by the final Version of Record.
Subject of Research: Molecularly targeted treatments and pathophysiology of brain arteriovenous malformations
Article Title: Targeted treatments for brain arteriovenous malformations: a review
Article References: Jung, J. Y., Radovanovic, I., & Bailey, A. (2026). Targeted treatments for brain arteriovenous malformations: a review. Acta Neurochirurgica. https://doi.org/10.1007/s00701-026-07046-4
Image Credits: AI Generated
DOI: 10.1007/s00701-026-07046-4
Keywords: brain arteriovenous malformations, targeted therapy, molecular profiling, somatic mutations, neurovascular disease, Acta Neurochirurgica, genotype-driven care, endothelial cells, Targeted, treatments, brain, arteriovenous
News Source: Cassandra Pierce. (November 10, 2026). Review Details Targeted Therapies for Brain AVMs. Scienmag.



